Creutzfeldt-Jakob Disease (CJD) Market Research Report, by type (Sporadic CJD, Hereditary CJD), diagnosis (imaging, brain biopsy), treatment (opiate drugs, clonazepam, sodium valproate), end users (hospitals, clinics) - global forecast till 2030

Creutzfeldt-Jakob disease (CJD) market Scenario:

The Creutzfeldt-Jakob Disease (CJD) Market is anticipated to reach USD 19,275.14 Million by 2030 at 23.90% CAGR during the forecast period 2022-2030. Creutzfeldt-Jakob disease or CJD is a rare, degenerative brain disorder which may lead to dementia and sudden death. The early stage symptoms of the disease include failing memory and lack of coordination followed by visual disturbances. As the disease progresses, mental deterioration becomes prominent leading to weakness of extremities, and conditions like coma. The CJD disease can be classified into three major groups, namely sporadic CJD, hereditary CJD, and acquired CJD. Sporadic CJD is the most common form of the disease and accounts for approximately 85% of the total reported cases. A majority of the treatments available in the market are symptomatic and aimed at alleviating pain.   The risk factors for the development of the disease are inclusive of old age, familial CJD genetics, and others. Increasing prevalence of Creutzfeldt-Jakob disease and growing geriatric population are estimated to be the major drivers for the market growth during the forecast period. In 2017, the National Institute of Neurological Disorders and Stroke stated that approximately 300 new cases of CJD are reported every year within the U.S. Moreover, it has been estimated that the symptomatic onset of the medical condition occurs predominantly around the age of 60. Additionally, according to the United States Census Bureau, the global geriatric population is projected to more than double and reach 1.6 billion from 2025 to 2050. Additionally, factors such as increasing per capita healthcare expenditure and extensive research and development by the market players will drive the market growth. However, lack of awareness, limited availability of therapeutics, and erroneous diagnostic results are estimated to restrain the Creutzfeldt-Jakob disease (CJD) market growth during the forecast period.

Intended Audience

• Pharmaceutical companies


• Biotechnological institutes


• Government and Private Laboratories


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Market Research and Consulting Service Providers

Figure 1- Creutzfeldt-Jakob Disease (CJD) Market Share, by Region

Sources: National Institute of Neurological Disorders and Stroke, United States Census Bureau, Age UK, Indian Brand Equity Foundation, annual reports, press release, white paper, and company presentation

Segmentation

The Creutzfeldt-Jakob disease (CJD) market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of the type, the market is segmented into sporadic CJD, hereditary CJD, and acquired CJD. On the basis of the diagnosis, the market is categorized into imaging, spinal fluid tests, brain biopsy, and others. The imaging segment is sub-segmented into electroencephalogram (EEG), magnetic resonance imaging (MRI), computerized tomography (CT), and others. On the basis of the treatment, the market is segmented into opiate drugs, clonazepam, sodium valproate, and others.  On the basis of the end users, the market is segmented into hospitals & clinics, research organizations, diagnostic centers, medical research institutes, and others.

Research Methodology

Sources: National Institute of Neurological Disorders and Stroke, United States Census Bureau, Age UK, Indian Brand Equity Foundation, annual reports, press release, white paper, and company presentation

Regional Analysis

The Americas dominate the global market for Creutzfeldt-Jakob disease (CJD) market due to a huge patient population, presence of a well-developed healthcare sector, and market key players like Mylan N.V., GENERAL ELECTRIC, Apotex Inc., and others within the region. Moreover, changing lifestyle and growing healthcare expenditure fuels the market within the regional boundaries of the Americas.

Europe is second in the Creutzfeldt-Jakob disease (CJD) market owing to the availability of funds for research and development and growing geriatric population. In 2018, according to the Age UK, there are approximately 11.8 million people aged 65 or above within U.K. Regionally, Europe is divided into Western Europe and Eastern Europe. Western Europe leads the market due to the presence of developed economies like Italy, U.K, France, and others.

Asia Pacific is estimated to be the fastest growing region for the Creutzfeldt-Jakob disease (CJD) market. This can be attributed due to the increasing geriatric population and a continuously developing healthcare sector within the region.  According to the Indian Brand Equity Foundation in 2016, the Indian healthcare sector was projected to be one of the fastest growing industries. The healthcare sector in India is expected to grow at a CAGR of 22.87% from 2015 to 2020, reaching USD 280 billion by 2020.

On the other hand, the Middle East & Africa holds the least share in the Creutzfeldt-Jakob disease (CJD) market due to the presence of poor economies, and stringent government policies, especially within the African region. A majority of the Middle East & African region is estimated to be held by the Middle East due to the presence of developed economies like Kuwait, Qatar, Dubai, and others.

Key players

Some of the key players for the Creutzfeldt-Jakob disease (CJD) market are Teva Pharmaceutical Industries Ltd. (Israel), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V.  (U.S.), Sandoz International GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), Apotex Inc. (Canada), Par Pharmaceutical. (U.S.), GENERAL ELECTRIC (U.S.), Koninklijke Philips N.V. (The Netherlands), Medtronic (U.S.), Siemens AG (Germany), Accuray Incorporated (U.S.), and others.